6 completed, 2 terminated, 1 unknown. 9 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 6, Terminated 2, Unknown 1 |
| Phase 1 | 1 | Terminated 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Interleukin-11: new trials by email Literature Review of Interleukin-11 trials Research Report on Interleukin-11
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Megakaryocytic Progenitor Cells for Prophylaxis and Treatment of Thrombocytopenia MPs, thrombopoietin (TPO) and interleukin-11 - Hematological Diseases, Thrombocytopenia | Phase 2 / Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 250 | 2014-09-01 | 2014-09-16 |
| Efficacy and Safety of IL-11 in DDAVP Unresponsive Neumega (Oprelvekin, Interleukin 11, IL-11) - Hemophilia A, Von Willebrand Disease | Phase 2 | Completed | University of Pittsburgh | 9 | 2010-01-01 | 2016-03-02 |
| IL-11 in Adults With Von Willebrand Disease Undergoing Surgery Neumega (Oprelvekin, Interleukin 11, IL-11) - Von Willebrand Disease | Phase 2 | Terminated | Margaret Ragni | 3 | 2008-02-01 | 2019-06-11 |
| IL-11 in Women With Von Willebrand Disease and Refractory Menorrhagia Oprelvekin, Interleukin 11, IL-11 - Von Willebrand Disease | Phase 2 | Completed | Margaret Ragni | 7 | 2008-01-01 | 2018-01-31 |
| Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients Interleukin-11 (IL-11 or Neumega) - Leukemia, Chronic Myelogenous Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 8 | 2005-10-01 | 2012-02-20 |
| Phase II Study of IL-11 (Neumega) in Von Willebrand Disease recombinant interleukin-11 - Von Willebrand Disease | Phase 2 | Completed | University of Pittsburgh | 12 | 2004-07-01 | 2016-05-17 |
| Study Evaluating rhIL-11 in Active Crohn's Disease Recombinant Human Interleukin-11 (rhIL-11) - Crohn Disease, Inflammatory Bowel Disease | Phase 2 | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 2002-04-01 | 2013-02-08 | |
| Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma rituximab, yttrium Y 90 ibritumomab tiuxetan, indium In 111 ibritumomab tiuxetan - Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 81 | 2001-04-01 | 2018-08-09 |
| Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors filgrastim, recombinant interleukin-11 - Breast Cancer, Gestational Trophoblastic Tumor | Phase 2 | Completed | Fred Hutchinson Cancer Center | 2000-08-01 | 2010-04-02 |
von Willebrand Diseases (4) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, B-Cell, Marginal Zone (2) · Lymphoma, Follicular (2) · Thrombocytopenia (2) · Breast Neoplasms (1) · Burkitt Lymphoma (1) · Carcinoma, Embryonal (1) · Carcinoma, Ovarian Epithelial (1) · Crohn Disease (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Endodermal Sinus Tumor (1) · Gestational Trophoblastic Disease (1) · Hematologic Diseases (1) · Hemophilia A (1)
Margaret Ragni (2) · University of Pittsburgh (2) · Fred Hutchinson Cancer Center (1) · M.D. Anderson Cancer Center (1) · Nanfang Hospital, Southern Medical University (1) · National Cancer Institute (NCI) (1) · Wyeth is now a wholly owned subsidiary of Pfizer (1)
United States (8) · China (1)
Margaret V. Ragni, MD, MPH (3) · Jorge E. Cortes, MD (1) · Leona A. Holmberg, MD, PhD (1) · Margaret V Ragni, MD, MPH (1) · Qifa Liu, MD (1) · Thomas Witzig (1)